藥品參考
Remibrutinib
Remibrutinib is a medicine in the class oncology. It is used for urticaria.
- 藥物類別: Oncology
- 用途: urticaria
最後更新 來源: US FDA label
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- ATC 代碼
- L04AA60
- 常見劑型
- 錠劑
- 常見規格
- 25 mg
- 已知交互作用
- 1 (中度: 1)
- 商品名
- 2
- 國家與市場
- 2
用途
作用方式
Oral small molecule kinase inhibitor of Bruton's tyrosine kinase (BTK), which is involved in FcεR1, FcγR and B cell receptor signaling. It inhibits mast cell and basophil degranulation, including histamine release.
成人常用劑量（仿單摘要）
Chronic spontaneous urticaria (adults symptomatic despite H1 antihistamine): 25 mg orally twice daily with or without food.
懷孕與哺乳
- 懷孕
- Unknown Human data are insufficient. Rabbits had external malformations at 141 times human exposure; rats showed no effects at 126 times. A pregnancy registry exists. Use only if the benefit justifies the risk.
- 哺乳
- Safe No data on milk levels or infant effects. Highly protein bound with a half-life under 2 hours, so milk levels are likely low. US label: weigh benefits. LactMed: not a reason to discontinue breastfeeding.
已通報的副作用
- Nasopharyngitis
- Bleeding
- Headache
- Nausea
- Abdominal pain
哪些人需要特別留意
- Risk of bleeding: mucocutaneous bleeding occurred in 9% of patients. Monitor for bleeding and interrupt treatment if it is observed. Antithrombotic agents may further increase the risk.
- Avoid live or live-attenuated vaccines in patients receiving the drug; no data are available.
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (1)
- Digoxin + Remibrutinib Moderate
Pro+ 會員專屬
解鎖完整頁面
建立帳號並開始 Pro+ 試用，即可開啟 Remibrutinib 的完整藥品專論：劑量、懷孕與哺乳、副作用、警示及所有交互作用。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
在網頁版免費試用 Pro+ 7 天，無需信用卡。
同類別的其他藥品
常見問題
What is Remibrutinib used for?
Remibrutinib is a medicine in the class oncology. It is used for Urticaria.
What side effects have been reported with Remibrutinib?
Nasopharyngitis, Bleeding, Headache, Nausea, Abdominal pain.
Can Remibrutinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unknown. Human data are insufficient. Rabbits had external malformations at 141 times human exposure; rats showed no effects at 126 times. A pregnancy registry exists. Use only if the benefit justifies the risk. Breastfeeding: Safe. No data on milk levels or infant effects. Highly protein bound with a half-life under 2 hours, so milk levels are likely low. US label: weigh benefits. LactMed: not a reason to discontinue breastfeeding.
What does Remibrutinib interact with?
MediHelp lists 1 known interactions for Remibrutinib. Moderate: 1. The most serious include Digoxin.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
